The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
Abstract
Interleukin 13 (IL13) is a T-helper type 2 (Th2) cytokine associated with inflammation and pathology in allergic diseases such as bronchial asthma. We have shown that treatment with lebrikizumab, an anti-IL13 monoclonal antibody, significantly improves prebronchodilator forced expiratory volume in 1 s (FEV(1)) in a subset of subjects with uncontrolled asthma.To evaluate efficacy and safety of lebrikizumab in subjects with mild asthma who...
Paper Details
Title
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
Published Date
Dec 20, 2013
Volume
44
Issue
1
Pages
38 - 46
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History